Skip to content

The effect of local anesthetic infiltration to the nerves which lies on pectoral (chest) muscles on postoperative ( after operation) analgesia and opioid ( narcotic analgesics) consumption in aesthetic breast surgery operation.

The effect of pectoral nerve blocks on postoperative analgesia and opioid consumption in aesthetic breast surgery operation.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617000687392
Enrollment
54
Registered
2017-05-12
Start date
2017-05-15
Completion date
2018-04-30
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Using opioids for postoperative analgesia is a standard modality. But opioid related side effects like nausea-vomiting, respiratory depression, urinary retention, Pruritus limits its use. Peripheral nerve and truncus block with local anesthetics can improve postoperative analgesia and reduce opioid requirement. Our primary purpose in this study ; to investigate effect of pectoral nerve blocks on postoperative analgesia and total opioid consumption in aesthetic breast surgery operation.. We will take written informed consent for all patients before the procedure. We will record age, height, weight, American Society of Anesthesiologists (ASA) physical status of all patients.We will randomize patients into two group with computer program.In the operation room, we will routinely monitor electrocardiography, peripheric oxygen saturation and blood pressure.Standard anesthesia induction will perform for general anesthesia. At the end of breast surgery operation we will perform pectoral nerve blocks patients in intervention group. After skin disinfection first we will give 20 cc %0.25 bupivacaine fascia which lies between pectoralis minor and serratus anterior muscles between 3. and 4. ribs guided under ultrasound view. Then the same amount of bupivacaine will be given fascia which lies between pectoralis major and minor muscles. We will use appropriate needles for this intervention.It will take approximately 5 minutes. Both group ( control and intervebntion group) will take same postoperative analgesics routinely. Postoperative analgesia will provided with patient controlled analgesia (PCA) device which contains opioid drugs. Postoperative analgesia will measure with visual analog scale for pain and opioid consumption with PCA datas postoperative 0,1,2,4,6,8,12 and 24. hours .

Interventions

At the end of breast surgery operation anesthesiologists will perform pectoral nerve blocks patients in intervention group. After skin disinfection first anesthesiologists will give 20 ml %0.25 bupivacaine to fascia which lies between pectoralis minor and serratus anterior muscles between 3. and 4. ribs guided under ultrasound view. Then the same amount of bupivacaine will be given fascia which lies between pectoralis major and minor muscles. We will use appropriate needles for this interventi

At the end of breast surgery operation anesthesiologists will perform pectoral nerve blocks patients in intervention group. After skin disinfection first anesthesiologists will give 20 ml %0.25 bupivacaine to fascia which lies between pectoralis minor and serratus anterior muscles between 3. and 4. ribs guided under ultrasound view. Then the same amount of bupivacaine will be given fascia which lies between pectoralis major and minor muscles. We will use appropriate needles for this intervention.It will take approximately 5 minutes.

Sponsors

Baskent University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1) Will undergo Aesthetic breast surgery operation 2)between 20-65 years old 3)American Society of Anesthesiologists (ASA) physical status I-II patients.

Exclusion criteria

1)antiepileptic drug use 2)Known allergy to study drugs 3)Severe renal or hepatic disease 4)Psychiatric disorders 5) Routine use of opioids or NSAI drugs 6)Pregnancy or lactation 7)Neurpathic disorders 8) Rejects study participation or using patient controlled analgesia device

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026